Table 1 Baseline information of SLE patients
Characteristic | SLE patients(n = 101) |
|---|---|
Age(years) | 27.54 ± 10.68 |
Disease duration(months) | 44.74 ± 47.84 |
Gender | |
Female | 93(92.1%) |
Male | 8(7.9%) |
Immunological indicators | |
Anti-dsDNA positivity rate | 74(73.3%) |
Hypocomplementemia | 90(89.1%) |
Clinical manifestation | |
Leucopenia | 38(37.6%) |
Thrombocytopenia | 17(16.8%) |
Rash | 71(70.3%) |
Alopecia | 35(34.7%) |
Mucosal ulcers | 24(23.8%) |
Arthritis | 66(65.3%) |
Serositis | 22(21.8%) |
Neurological/psychiatric symptoms | 7(6.9%) |
Lupus nephritis | 56(55.4%) |
Disease assessment indicators | |
SLEDAI-2k | 12.5 ± 3.9 |
PGA | 1.7 ± 0.3 |
Use of antimalarials (hydroxychloroquine) | 96(95.0%) |
Use of immunosuppressive agents | |
Mycophenolate mofetil | 54(53.5%) |
Cyclophosphamide | 5(5.0%) |
Tacrolimus | 17(16.8%) |
Mycophenolate mofetil＋Tacrolimus | 6(6.0%) |
Cyclosporine A | 4(4.0%) |
Methotrexate | 3(3.0%) |
Leflunomide | 8(7.9%) |
Prednisone dosage(mg/d) | 33.57 ± 15.13 |